Omalizumab as Effective as Immunotherapy for Food Allergies

- Omalizumab, marketed as Xolair, is a lab-engineered antibody that works by targeting and blocking Immunoglobulin E (IgE), the specific antibody your immune system produces during an allergic reaction. This prevents IgE from binding to mast cells and basophils, which in turn stops the release of histamine and other chemicals that cause allergy symptoms. - Oral immunotherapy (OIT) operates on a different principle of desensitization, where a patient consumes gradually increasing doses of their specific food allergen over several months. The goal is to retrain the immune system to tolerate the food, thereby reducing the severity of reactions to accidental exposures. - This head-to-head comparison was part of a landmark clinical trial called OUtMATCH (Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults), sponsored by the National Institutes of Health (NIH). The lead author of the study was Dr. Robert A. Wood, Director of the Eudowood Division of Allergy, Immunology and Rheumatology at Johns Hopkins Children's Center. - A key difference found in the study was the rate of adverse side effects. While no participants in the omalizumab group experienced serious adverse reactions, over 30% of those in the OIT group did. This led to a much higher dropout rate for the OIT group, with only 51% completing the trial compared to 88% in the omalizumab group. - The study included participants allergic to peanuts and at least two other common foods, including milk, eggs, wheat, cashews, walnuts, and hazelnuts. Success was defined as being able to tolerate at least 4,044 mg of all three allergenic foods, which is equivalent to about 20 peanuts or half a cup of milk. - This type of clinical trial involves a variety of life science careers. Patient-facing roles, like those held by M.D.s and clinical research coordinators, involve designing the study, recruiting and monitoring patients, and analyzing clinical data. - Behind the scenes, professionals in biotechnology and pharmaceuticals with PhDs or other advanced degrees focus on the drug development itself. Their work includes the initial laboratory research to discover the drug's mechanism, developing manufacturing processes, and ensuring the drug is safe for human trials, often involving bioinformatics and computational biology to model interactions. - Following the positive results, researchers are now analyzing preliminary data from a third stage of the study to see if patients can successfully introduce allergenic foods into their diets after stopping omalizumab treatment.